Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameluz versus Metvix PDT for non-aggressive basal cell carcinoma
2013-003241-42Phase 3Completed
- Sponsor
- Biofrontera
- Start
- Nov 2013
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in basal cell carcinoma (BCC) comparing Ameluz PDT with Metvix PDT (2 arms). Primary endpoint: Overall patient complete response. Started Nov 2013; status: completed.
02
Drugs
5-aminolevulinic acidmethyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2013-003241-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003241-42.